NVIC Articles

Respiratory-Syncytial-Virus-(RSV)

Disease-Vaccine-Landing-Page/Respiratory-Syncytial-Virus-(RSV)

Latest articles

Browse Articles

Placeholder image
Page

In pre-licensing clinical trials, the most frequently reported side effect was injection site pain. Within seven days of receipt of MRESVIA, the most commonly reported systemic adverse events included fatigue,...

Placeholder image
Page

On July 17, 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV in infants and children up to 24 months...

Placeholder image
Page

According to Moderna, at 3.7 months following administration, MRESVIA RSV vaccine efficacy was reported to be 78.7 percent against RSV illness with two or more symptoms of lower respiratory tract...

Placeholder image
Page

According to GSK, AREXVY RSV vaccine efficacy was reported to be 82.6 percent against the first occurrence of RSV related lower respiratory tract infection in persons 60 through 79 years...

Placeholder image
Page

Pfizer reports that the vaccine efficacy in infants born from mothers who received the RSV vaccine during the third trimester of pregnancy was 57.1 percent at 90 days after birth,...

Placeholder image
Page

In the pre-licensing clinical trial, Pfizer reported vaccine efficacy to be 66.7 percent against the first episode of RSV-related lower respiratory tract infection with two or more symptoms, and had...

Placeholder image
Page

On July 17, 2023 the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV. Though the CDC has determined that it...

Placeholder image
Page

On May 31, 2024, the FDA approved MRESVIA, an mRNA RSV vaccine manufactured by Moderna, for use in persons 60 years of age and older. The approval of MRESVIA was...

Placeholder image
Page

In August 2022, Pfizer issued a press release announcing the success of their Phase 3 clinical trial of a bivalent RSV prefusion F vaccine candidate, RSVpreF, in persons 60 years...

Placeholder image
Page

In October 2022, GlaxoSmithKline (GSK) pharmaceutical issued a press release that reported their RSV vaccine reduced severe RSV illness by 94.1 percent in persons 60 years and older. GSK also...

Topics
Select disease / vaccine